ISDA

Deposition Date 2019-03-25

Release Date 2019-05-08

Last Version Date 2024-03-13

Entry Detail

PDB ID:

6OCQ

Keywords:

SIGNALING PROTEIN/INHIBITOR

Title:

Crystal structure of RIP1 kinase in complex with a pyrrolidine

Biological Source:

Source Organism:

Homo sapiens (Taxon ID: 9606)

Host Organism:

Spodoptera aff. frugiperda 2 RZ-2014

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.79 Å

R-Value Free:

0.26

R-Value Work:

0.20

R-Value Observed:

0.20

Space Group:

P 21 21 21

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Receptor-interacting serine/threonine-protein kinase 1
Gene (Uniprot):RIPK1
Mutations:C34A, C127A, C233A, C240A
Chain IDs:A, B
Chain Length:303
Number of Molecules:2
Biological Source:Homo sapiens

UniProt ID:Q13546 Pfam ID:PF07714 EC:2.7.10.2

Ligand Molecules

M5J

SO4

Primary Citation

Discovery and Lead-Optimization of 4,5-Dihydropyrazoles as Mono-Kinase Selective, Orally Bioavailable and Efficacious Inhibitors of Receptor Interacting Protein 1 (RIP1) Kinase.

Harris, P.A, Faucher, N, George, N, Eidam, P.M, King, B.W, White, G.V, Anderson, N.A, Bandyopadhyay, D, Beal, A.M, Beneton, V, Berger, S.B, Campobasso, N, Campos, S, Capriotti, C.A, Cox, J.A, Daugan, A, Donche, F, Fouchet, M.H, Finger, J.N, Geddes, B, Gough, P.J, Grondin, P, Hoffman, B.L, Hoffman, S.J, Hutchinson, S.E, Jeong, J.U, Jigorel, E, Lamoureux, P, Leister, L.K, Lich, J.D, Mahajan, M.K, Meslamani, J, Mosley, J.E, Nagilla, R, Nassau, P.M, Ng, S.L, Ouellette, M.T, Pasikanti, K.K, Potvain, F, Reilly, M.A, Rivera, E.J, Sautet, S, Schaeffer, M.C, Sehon, C.A, Sun, H, Thorpe, J.H, Totoritis, R.D, Ward, P, Wellaway, N, Wisnoski, D.D, Woolven, J.M, Bertin, J, Marquis, R.W.Show

J.Med.Chem. 62 5096 5110 (2019)

PMID: 31013427 DOI: 10.1021/acs.jmedchem.9b00318

Abstact

RIP1 kinase regulates necroptosis and inflammation and may play an important role in contributing to a variety of human pathologies, including inflammatory and neurological diseases. Currently, RIP1 kinase inhibitors have advanced into early clinical trials for evaluation in inflammatory diseases such as psoriasis, rheumatoid arthritis, and ulcerative colitis and neurological diseases such as amyotrophic lateral sclerosis and Alzheimer's disease. In this paper, we report on the design of potent and highly selective dihydropyrazole (DHP) RIP1 kinase inhibitors starting from a high-throughput screen and the lead-optimization of this series from a lead with minimal rat oral exposure to the identification of dihydropyrazole 77 with good pharmacokinetic profiles in multiple species. Additionally, we identified a potent murine RIP1 kinase inhibitor 76 as a valuable in vivo tool molecule suitable for evaluating the role of RIP1 kinase in chronic models of disease. DHP 76 showed efficacy in mouse models of both multiple sclerosis and human retinitis pigmentosa.

Legend

Protein

Chemical

Disease

Primary Citation of related structures